Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer and the fourth leading cause of cancer-related death, has a 5-year survival rate of less than 10%.1 The impact of pancreatic ...

Cash expected to fund operations into the second half of 2026Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma ...

Cash expected to fund operations into the second half of 2026Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multif ...

Operator: Good afternoon, and welcome to Oncolytics Biotech First Quarter Conference Call. All participants are in a listen-only mode.

Strategic focus on exploratory investigator-initiated clinical studies with institutional partnersContinued progress of DNase I development program towards IND and first-in-human study for treatment ...

RenovoRx, Inc. ("RenovoRx" or the "Company") , a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath©, a novel, FDA-cleared drug-delivery device, ...

Disney star and comedian Rondell Sheridan, best known for his role on "That's So Raven" has been hospitalized due to severe pancreatitis ...

Discover the connections between dental cavities, oral health, and cancer risk, including inflammation pathways, immune ...

ROCKVILLE, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage ...

VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial - - Closed a public offering on May 8, 2025, raising the Company's cash ...

Enrollment and dosing underway in Phase 3 clinical trial (the“MIRACLE” trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML </p ...

Type 5 diabetes has just been recognised as a distinct form of diabetes by the International Diabetes Federation.